Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors

Class B G-protein-coupled receptors (GPCRs) are receptors for peptide hormones that include glucagon, parathyroid hormone, and calcitonin. These receptors are involved in a wide spectrum of physiological activities, from metabolic regulation and stress control to development and maintenance of the skeletal system. As such, they are important drug targets for the treatment of diabetes, osteoporosis, and stress related disorders. Class B GPCRs are organized into two modular domains: an extracellular domain (ECD) and a helical bundle that contains seven transmembrane helices (TM domain). The ECD is responsible for the high affinity and specificity of hormone binding, and the TM domain is required for receptor activation and signal coupling to downstream G-proteins. Although the structure of the full-length receptor remains unknown, the ECD structures have been well characterized for a number of Class B GPCRs, revealing a common fold for ligand recognition. This review summarizes the general structural principles that guide hormone binding by Class B ECDs and their implications in the design of peptide hormone analogs for therapeutic purposes.

[1]  I. Gozes,et al.  Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability , 2008, Journal of peptide science : an official publication of the European Peptide Society.

[2]  B. Wulff,et al.  Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity , 2003, British journal of pharmacology.

[3]  P. Sexton,et al.  Pattern of Intra-Family Hetero-Oligomerization Involving the G-Protein-Coupled Secretin Receptor , 2008, Journal of Molecular Neuroscience.

[4]  S. Goldring,et al.  Full Activation of Chimeric Receptors by Hybrids between Parathyroid Hormone and Calcitonin , 1996, The Journal of Biological Chemistry.

[5]  B. Gallwitz The evolving place of incretin-based therapies in type 2 diabetes , 2010, Pediatric Nephrology.

[6]  R. Riek,et al.  NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Hajduk,et al.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS , 2007, Proceedings of the National Academy of Sciences.

[8]  Anthony J Harmar,et al.  Family-B G-protein-coupled receptors , 2001, Genome Biology.

[9]  R. Lefkowitz,et al.  Distinct β-Arrestin- and G Protein-dependent Pathways for Parathyroid Hormone Receptor-stimulated ERK1/2 Activation* , 2006, Journal of Biological Chemistry.

[10]  L. Nabors,et al.  Improved social and language skills after secretin administration in patients with autistic spectrum disorders. , 1998, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.

[11]  T. Usdin,et al.  Molecular determinants of tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2 (PTH2) receptor. N-terminal truncation of TIP39 reverses PTH2 receptor/PTH1 receptor binding selectivity. , 2000, The Journal of biological chemistry.

[12]  F. Grégoire,et al.  Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency , 2004, Peptides.

[13]  Leonardo Pardo,et al.  Ligand-regulated oligomerization of β2-adrenoceptors in a model lipid bilayer , 2009, The EMBO journal.

[14]  H. Xu,et al.  Crystal Structure of the PAC1R Extracellular Domain Unifies a Consensus Fold for Hormone Recognition by Class B G-Protein Coupled Receptors , 2011, PloS one.

[15]  C. Koth,et al.  Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. , 2010, Structure.

[16]  R. Riek,et al.  NMR Structure of the First Extracellular Domain of Corticotropin-releasing Factor Receptor 1 (ECD1-CRF-R1) Complexed with a High Affinity Agonist* , 2010, The Journal of Biological Chemistry.

[17]  S. Yokoyama,et al.  Crystal structure of the human receptor activity‐modifying protein 1 extracellular domain , 2008, Protein science : a publication of the Protein Society.

[18]  H. Xu,et al.  Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.

[19]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[20]  Lotte Bjerre Knudsen,et al.  Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor* , 2009, The Journal of Biological Chemistry.

[21]  L. Jingjing,et al.  Study on preparation and activity of a novel recombinant human parathyroid hormone(1–34) analog with N-terminal Pro–Pro extension , 2007, Regulatory Peptides.

[22]  T. Gardella,et al.  Parathyroid Hormone (PTH)-(1–14) and -(1–11) Analogs Conformationally Constrained by α-Aminoisobutyric Acid Mediate Full Agonist Responses via the Juxtamembrane Region of the PTH-1 Receptor* , 2001, The Journal of Biological Chemistry.

[23]  N. Tinel,et al.  Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization , 2008, Nature Methods.

[24]  Vsevolod V Gurevich,et al.  How and why do GPCRs dimerize? , 2008, Trends in pharmacological sciences.

[25]  C. Goudet,et al.  Allosteric functioning of dimeric class C G‐protein‐coupled receptors , 2005, The FEBS journal.

[26]  I. Campbell,et al.  Three-dimensional structure of a complement control protein module in solution. , 1991, Journal of molecular biology.

[27]  R. Rudolph,et al.  Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor , 2007, Proceedings of the National Academy of Sciences.

[28]  B. Wiesner,et al.  Dimerization of Corticotropin-Releasing Factor Receptor Type 1 Is Not Coupled to Ligand Binding , 2005, Journal of receptor and signal transduction research.

[29]  H. Xu,et al.  Structural Basis for Hormone Recognition by the Human CRFR2α G Protein-coupled Receptor* , 2010, The Journal of Biological Chemistry.

[30]  R. Rudolph,et al.  Passing the baton in class B GPCRs: peptide hormone activation via helix induction? , 2009, Trends in biochemical sciences.

[31]  H. Xu,et al.  Structural Basis for Parathyroid Hormone-related Protein Binding to the Parathyroid Hormone Receptor and Design of Conformation-selective Peptides* , 2009, The Journal of Biological Chemistry.

[32]  Richard R. Neubig,et al.  International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List , 2005, Pharmacological Reviews.

[33]  L. Miller,et al.  Critical Contributions of Amino-terminal Extracellular Domains in Agonist Binding and Activation of Secretin and Vasoactive Intestinal Polypeptide Receptors. STUDIES OF CHIMERIC RECEPTORS (*) , 1995, The Journal of Biological Chemistry.

[34]  L. B. Knudsen,et al.  Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. , 2000, Journal of medicinal chemistry.

[35]  M. Wheeler,et al.  Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. , 2001, Biochemistry.

[36]  P. Sexton,et al.  Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs. , 2006, Annals of the New York Academy of Sciences.

[37]  H. Randeva,et al.  Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. , 2000, Molecular endocrinology.

[38]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[39]  Patrick M. Sexton,et al.  International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors , 2002, Pharmacological Reviews.

[40]  Monitoring the structural consequences of Phe12-->D-Phe and Leu15-->Aib substitution in human/rat corticotropin releasing hormone. Implications for design of CRH antagonists. , 2001, European journal of biochemistry.

[41]  Helgi B. Schiöth,et al.  Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.

[42]  A. Couvineau,et al.  VPAC receptors for VIP and PACAP. , 2002, Receptors & channels.

[43]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. , 2000, Pharmacological reviews.

[44]  W. Creutzfeldt,et al.  Gastric inhibitory polypeptide. , 1980, Clinics in gastroenterology.

[45]  H. Xu,et al.  Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1* , 2008, Journal of Biological Chemistry.

[46]  Krzysztof Palczewski,et al.  Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors. , 2006, Current opinion in structural biology.

[47]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[48]  B. Wulff,et al.  Three Distinct Epitopes on the Extracellular Face of the Glucagon Receptor Determine Specificity for the Glucagon Amino Terminus* , 2003, Journal of Biological Chemistry.

[49]  M. Palkovits,et al.  The TIP39–PTH2 receptor system: Unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms , 2010, Progress in Neurobiology.

[50]  M. Nauck,et al.  Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. , 2004, Diabetes.

[51]  Roland Baron,et al.  The Alternatively Spliced Δe13 Transcript of the Rabbit Calcitonin Receptor Dimerizes with the C1a Isoform and Inhibits Its Surface Expression* , 2003, Journal of Biological Chemistry.

[52]  N. Ling,et al.  NMR Structural Characterization of a Minimal Peptide Antagonist Bound to the Extracellular Domain of the Corticotropin-releasing Factor1 Receptor* , 2007, Journal of Biological Chemistry.

[53]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[54]  Y. Yamada [Gastric inhibitory polypeptide (GIP) receptor]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[55]  E. Krause,et al.  A Role for a Helical Connector between Two Receptor Binding Sites of a Long-chain Peptide Hormone* , 2000, The Journal of Biological Chemistry.

[56]  L. Miller,et al.  Transmembrane Segment IV Contributes a Functionally Important Interface for Oligomerization of the Class II G Protein-coupled Secretin Receptor* , 2007, Journal of Biological Chemistry.

[57]  Laurence J Miller,et al.  Constitutive Formation of Oligomeric Complexes between Family B G Protein-Coupled Vasoactive Intestinal Polypeptide and Secretin Receptors , 2006, Molecular Pharmacology.

[58]  W. Vale,et al.  CRF and CRF receptors: role in stress responsivity and other behaviors. , 2004, Annual review of pharmacology and toxicology.

[59]  Masatsugu Horiuchi,et al.  London Radiation Symposium , 1963, Cell and tissue kinetics.

[60]  Kjeld Madsen,et al.  Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain* , 2008, Journal of Biological Chemistry.

[61]  G. Hall 12 – X-Ray Analysis , 1984 .

[62]  L. Frohman,et al.  Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. , 2006, The Journal of clinical endocrinology and metabolism.

[63]  Gregory I. Mashanov,et al.  Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules , 2010, Proceedings of the National Academy of Sciences.

[64]  R. Lefkowitz,et al.  A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation , 2009, Science Translational Medicine.

[65]  L. Miller,et al.  Dimeric Arrangement of the Parathyroid Hormone Receptor and a Structural Mechanism for Ligand-induced Dissociation* , 2010, The Journal of Biological Chemistry.

[66]  S. Hoare,et al.  Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. , 2005, Drug discovery today.

[67]  C. Hewage,et al.  Conformational and molecular interaction studies of glucagon‐like peptide‐2 with its N‐terminal extracellular receptor domain , 2011, FEBS letters.

[68]  T. Usdin,et al.  TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus , 1999, Nature Neuroscience.

[69]  N. Irwin,et al.  C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. , 2008, Biochemical pharmacology.

[70]  Alon Chen,et al.  Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. , 2004, Endocrinology.

[71]  R. Riek,et al.  Common and divergent structural features of a series of corticotropin releasing factor-related peptides. , 2007, Journal of the American Chemical Society.

[72]  A. Couvineau,et al.  Class-B GPCR activation: is ligand helix-capping the key? , 2008, Trends in biochemical sciences.

[73]  R. Riek,et al.  Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand , 2007, Proceedings of the National Academy of Sciences.

[74]  J. Reeve,et al.  Parathyroid hormone - a bone anabolic and catabolic agent. , 2005, Current opinion in pharmacology.

[75]  T. Serwold,et al.  Chimeric human calcitonin and glucagon receptors reveal two dissociable calcitonin interaction sites. , 1995, Biochemistry.

[76]  Ian J. Tickle,et al.  X-ray analysis of glucagon and its relationship to receptor binding , 1975, Nature.

[77]  B. Persson,et al.  Model of the complex of Parathyroid hormone-2 receptor and Tuberoinfundibular peptide of 39 residues , 2010, BMC Research Notes.

[78]  T. Ikegami,et al.  Conformation of a peptide ligand bound to its G-protein coupled receptor , 2001, Nature Structural Biology.

[79]  C. Donaldson,et al.  Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[80]  W. Vale,et al.  Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation , 2008, Proceedings of the National Academy of Sciences.